Glaukos stock price target raised to $252 by BTIG on revenue outlook

BTIG raised Glaukos (GKOS) price target to $252 from $234, citing strong revenue outlook. GKOS shares are up 118% YTD. The company projected $1B FY2027 revenue, exceeding estimates. Q3 2026 revenue was $211M, up 58% YoY. Several firms raised price targets post-results.

Original reporting
Published Nov 16, 2026, 10:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GKOS
Bullish
high confidence
Mentioned
$GKOS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GKOSBullishMed
01

Why it matters

The guidance upgrade is the primary catalyst for a potential price rally.

02

Market read

Guidance lift and higher target could drive GKOS shares higher in the short term.

03

What to watch

Potential regulatory delays for new products could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

The article recaps analyst price‑target upgrades and Glaukos' FY2027 revenue guidance after its Q3 2026 results.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

BTIG raised its price target to $252 and Glaukos issued FY2027 revenue guidance of ~$1B, up from prior estimates.

Expected impact

likely upward pressure as investors price in higher revenue expectations

Evidence & confidence

The new $1B revenue outlook and higher target represent a material shift from prior guidance, prompting buying interest.

Market effects

Positive for the ophthalmic medical device sector as Glaukos' guidance may lift peers.

U.S. biotech and med‑tech stocks could see modest gains.

Limited to investors tracking eye‑care device manufacturers.

Counterpoint

If execution risks on Epioxa and iDose materialize, the guidance may be overly optimistic.

Key entities

  • Glaukos Corporation

    Medical technology firm specializing in glaucoma treatments.

  • BTIG

    Equity research firm raising price target.

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.